R Van Dyke
Overview
Explore the profile of R Van Dyke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malik S, Vranken P, Silio M, Ratard R, Van Dyke R
Epidemiol Infect
. 2009 Mar;
137(9):1237-41.
PMID: 19257914
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections are increasingly recognized in persons without established risk factors. Population-based prevalence studies of CA-MRSA colonization in persons without risk factors are relatively limited. Subjects...
2.
Acosta E, Zorrilla C, Van Dyke R, Bardeguez A, Smith E, Hughes M, et al.
HIV Clin Trials
. 2001 Dec;
2(6):460-5.
PMID: 11742433
Purpose: To evaluate saquinavir (SQV) pharmacokinetics, tolerance, and safety in 10 HIV-infected pregnant women between 14-32 weeks gestation. Method: This was a phase I, prospective, area-under-the-curve (AUC) targeted study. Antepartum...
3.
Saez-Llorens X, Nelson Jr R, Emmanuel P, Wiznia A, Mitchell C, Church J, et al.
Pediatrics
. 2001 Jan;
107(1):E4.
PMID: 11134468
Objectives: Abacavir (ABC) is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. We compared the efficacy, safety, and tolerability of combination therapy with ABC, lamivudine (3TC),...
4.
Lambert J, Watts D, Mofenson L, Stiehm E, Harris D, Bethel J, et al.
AIDS
. 2000 Aug;
14(10):1389-99.
PMID: 10930154
Objective: To evaluate independent contributions of maternal factors to adverse pregnancy outcomes (APO) in HIV-infected women receiving antiretroviral therapy (ART). Design: Risk factors for preterm birth (< 37 weeks gestation),...
5.
Kaplan J, Masur H, Holmes K, Freedberg K, Holtgrave D, Piscitelli S, et al.
Clin Infect Dis
. 2000 Apr;
30 Suppl 1:S15-28.
PMID: 10770912
No abstract available.
6.
Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, Mofenson L, et al.
J Infect Dis
. 2000 Mar;
181(3):890-6.
PMID: 10720509
Children of mothers infected with human immunodeficiency virus type 1 (HIV-1) were immunized at birth and at 1, 3, and 5 months with 1 of 3 doses of recombinant gp120...
7.
Hughes W, Dorenbaum A, Yogev R, Beauchamp B, Xu J, McNamara J, et al.
Antimicrob Agents Chemother
. 1998 Jun;
42(6):1315-8.
PMID: 9624466
A phase I dose-escalating safety and pharmacokinetic study evaluated an oral suspension of micronized atovaquone (m-atovaquone) in infants and children stratified into age groups from 1 month to 12 years...
8.
Mirochnick M, Capparelli E, Dankner W, Sperling R, Van Dyke R, Spector S
Antimicrob Agents Chemother
. 1998 Apr;
42(4):808-12.
PMID: 9559787
We used population analysis techniques to determine zidovudine (ZDV) pharmacokinetic parameters in 15 preterm neonates (mean gestational age, 29.4 weeks; mean birth weight, 1,230 g) at a mean age of...
9.
Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M, et al.
Pediatr Infect Dis J
. 1996 Mar;
15(3):247-54.
PMID: 8852914
Background: Neonatal herpes simplex virus (HSV) infections limited to the skin, eyes and mouth (SEM) can result in neurologic impairment. A direct correlation exists between the development of neurologic deficits...
10.
Robinson W, Wiley D, Van Dyke R
Infect Dis Obstet Gynecol
. 1995 Jan;
2(6):251-4.
PMID: 18475404
Objective: This study was undertaken to examine the effect of successive pregnancies over a 3-year period on the course of maternal human immunodeficiency virus (HIV) infection and the rate of...